CI Investments Inc. Has $6.34 Million Stock Position in Amgen Inc. $AMGN

Key Points

• CI Investments trimmed its stake in Amgen by 11.2% in Q3, selling 2,842 shares and ending the period with 22,449 shares worth about $6.335 million.
• Amgen declared a quarterly dividend of $2.52 per share (ex‑dividend May 15, payable June 5), equal to a $10.08 annualized payout and roughly a 2.7% yield.
• Amgen beat Q results (EPS $5.29 vs. $4.76 expected; revenue $9.87B) and set FY2026 guidance of $21.60–$23.00 EPS, while advancing its blinatumomab program into a Phase 3 subcutaneous trial—signals of both near‑term strength and potential future growth.

CI Investments Inc. lessened its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 11.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,449 shares of the medical research company's stock after selling 2,842 shares during the period. CI Investments Inc.'s holdings in Amgen were worth $6,335,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Legacy Investment Solutions LLC purchased a new position in shares of Amgen during the second quarter valued at approximately $27,000. Evelyn Partners Investment Management LLP bought a new position in Amgen during the 2nd quarter valued at $32,000. Howard Hughes Medical Institute purchased a new position in Amgen during the 2nd quarter worth $32,000. Cloud Capital Management LLC bought a new stake in shares of Amgen in the 3rd quarter worth $34,000. Finally, Nvwm LLC grew its stake in shares of Amgen by 893.3% in the 2nd quarter. Nvwm LLC now owns 149 shares of the medical research company's stock worth $42,000 after acquiring an additional 134 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Board declared a $2.52 per‑share dividend for Q2 2026 — a cash return and yield support that tends to be received positively by income and value investors. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Positive Sentiment: Amgen advanced its blinatumomab franchise with a new Phase 3 subcutaneous trial — if successful, a subcutaneous formulation can broaden use, improve patient convenience, and extend commercial life. This is a clinically material development for future revenue potential. Amgen Advances Blinatumomab Franchise With New Phase 3 Subcutaneous Trial
• Positive Sentiment: Stock reached an annual high within a Nasdaq‑100 rally — positive technical momentum and index strength can attract flows and lift shares. Amgen NASDAQ: AMGN Hits Annual High Within The Nasdaq 100 Index Rally
• Neutral Sentiment: Broader media and analyst coverage (Zacks, Yahoo Finance pieces) is raising investor attention but contains mainly summaries and guidance rechecks rather than new fundamental catalysts. Increased coverage can boost trading volume and visibility. Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Industry and market reports (asthma market outlook, competitor regulatory moves) are circulating; these are background items to monitor for longer‑term impact but not immediate stock drivers. 7MM Asthma Market Insights, Epidemiology, and Market Forecast Report 2022-2036
• Neutral Sentiment: Short‑interest entries in recent feeds report a "significant increase" but show zero shares/NaN figures — this appears to be a data error rather than a genuine surge in shorting. Until reliable short‑interest data is available, treat these reports cautiously. (Data entries from March 3–4 appear inconsistent.)

Amgen Price Performance

Shares of NASDAQ AMGN opened at $379.27 on Thursday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The stock has a fifty day simple moving average of $351.83 and a two-hundred day simple moving average of $321.58. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The firm has a market cap of $204.45 billion, a price-to-earnings ratio of 26.65, a price-to-earnings-growth ratio of 3.74 and a beta of 0.45.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts' consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion for the quarter, compared to analysts' expectations of $9.46 billion. During the same quarter in the prior year, the firm earned $5.31 EPS. The business's revenue for the quarter was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. Amgen's dividend payout ratio (DPR) is presently 70.84%.

Analyst Upgrades and Downgrades

AMGN has been the topic of several analyst reports. Sanford C. Bernstein cut shares of Amgen from an "outperform" rating to a "market perform" rating and set a $335.00 price target on the stock. in a report on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Amgen from $285.00 to $295.00 and gave the stock a "hold" rating in a research report on Thursday, February 5th. Guggenheim upped their target price on Amgen from $305.00 to $347.00 and gave the company a "neutral" rating in a report on Friday, February 6th. Truist Financial increased their price target on Amgen from $318.00 to $319.00 and gave the company a "hold" rating in a research report on Thursday, January 8th. Finally, Cantor Fitzgerald boosted their price objective on Amgen from $315.00 to $350.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $354.17.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.